Spots Global Cancer Trial Database for First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors
Official Title: An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous BAY 1179470 in Subjects With Advanced, Refractory Solid Tumors.
Study ID: NCT01881217
Conditions
Interventions
Study Description
Brief Summary: An open-label, non-randomized, Phase I dose-escalation study designed to assess the safety, tolerability, pharmacokinetics(PK) /pharmacodynamics( PD) and tumor response profile of BAY1179470 in subjects with advanced, refractory solid tumors
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Kashiwa, Chiba, Japan
, Kita-Adachigun, Saitama, Japan
, Chuo-ku, Tokyo, Japan
, Koto-ku, Tokyo, Japan
, Fukuoka, , Japan
, Seoul, , Korea, Republic of
, Singapore, , Singapore
, Singapore, , Singapore
Contact Details
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
